Romano Alessandra, Conticello Concetta, Cavalli Maide, Vetro Calogero, Di Raimondo Cosimo, Di Martina Valentina, Schinocca Elena, La Fauci Alessia, Parrinello Nunziatina Laura, Chiarenza Annalisa, Di Raimondo Francesco
Hematology Section, Department of Clinical and Molecular Biomedicine, University of Catania, Via Citelli 6, 95124 Catania, Italy ; Fondazione Veronesi, Via Lancellotti 18, 00186 Roma, Italy ; UOC di Ematologia con Trapianto di Midollo Osseo, Ospedale Ferrarotto, Via Citelli 6, 95124 Catania, Italy.
UOC di Ematologia con Trapianto di Midollo Osseo, Ospedale Ferrarotto, Via Citelli 6, 95124 Catania, Italy.
Biomed Res Int. 2014;2014:456037. doi: 10.1155/2014/456037. Epub 2014 May 19.
During the past decade, overall results of treatment of multiple myeloma (MM) have been improved and survival curves are now significantly better with respect to those obtained with historical treatment. These improvements are linked to a deeper knowledge of the biology of disease and to the introduction in clinical practice of drugs with different mechanism of action such as proteasome inhibitors and immunomodulatory drugs (IMiDs). However, MM remains in most cases an incurable disease. For patients who relapse after treatment with novel agents, the prognosis is dismal and new drugs and therapeutic strategies are required for continued disease control. In this review, we summarize new insights in salvage therapy for relapsed/refractory MM as emerging from recent clinical trials exploring the activity of bendamustine, new generation proteasome inhibitors, novel IMiDs, monoclonal antibodies, and drugs interfering with growth pathways.
在过去十年中，多发性骨髓瘤（MM）的总体治疗结果有所改善，与既往治疗相比，目前的生存曲线显著更好。这些改善与对疾病生物学的更深入了解以及具有不同作用机制的药物（如蛋白酶体抑制剂和免疫调节药物（IMiDs））在临床实践中的应用有关。然而，在大多数情况下，MM仍然是一种无法治愈的疾病。对于使用新型药物治疗后复发的患者，预后很差，需要新的药物和治疗策略来持续控制疾病。在本综述中，我们总结了复发/难治性MM挽救治疗的新见解，这些见解来自最近探索苯达莫司汀、新一代蛋白酶体抑制剂、新型IMiDs、单克隆抗体以及干扰生长途径药物活性的临床试验。
